Lilly launches four-dose Zepbound KwikPen in the US. Self-pay starter price begins at $299 per month. Move aims to improve retention in crowded GLP-1 market. Millions of people on GLP-1 weight-loss ...

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo Nordisk in the obesity drug race. While Novo’s shares have struggled this ...

Wegovy (semaglutide) does come in a pill form. In December of 2025, the Food and Drug Administration (FDA) approved Wegovy as an oral tablet. Wegovy injections and tablets contain the same active ...

Abstract: This brief presents an auto-correlated host sensing analog front-end (AFE) for active stylus systems, enabling host-stylus pairing without periodic display-disturbing beacon signals. The ...

Feb 12 (Reuters) - West Pharmaceutical (WST.N), opens new tab forecast annual profit above Wall Street estimates on Thursday, banking on higher demand for diabetes and obesity treatments that use its ...

'It's not an easy pill to take': The first highly anticipated GLP-1 pill is here, but physicians aren't sure it has the staying power of the injections Once you take the Wegovy pill in the morning, ...

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the ...